Feasibility of three times weekly symptom screening in pediatric cancer patients

• Published in: BMC cancer Vol. 23; no. 1; p. 4
• Main Authors: Calligan, Maryann, Chakkalackal, Lauren, Dadzie, Grace, Tardif-Theriault, Cassandra, Cook, Sadie, Vettese, Emily, Soman, Dilip, Kuczynski, Susan, Schechter, Tal, Dupuis, L Lee, Sung, Lillian
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 03.01.2023; BioMed Central; BMC
• Subjects: Cancer; Cancer in children; Care and treatment; Child; Diagnosis; Early Detection of Cancer; Feasibility Studies; Humans; Methods; Neoplasms - complications; Neoplasms - diagnosis; Oncology; Outcome and process assessment (Health Care); Pediatric; Pediatrics; Psychometrics; Quality of life; Services; Symptom Assessment; Symptom screening; Canada; Oncology; Pediatric; Symptom screening; Quality of life
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-10400-1

Primary objective was to determine the feasibility of three times weekly symptom reporting by pediatric cancer patients for eight weeks. We included English-speaking patients 8-18 years of age with cancer. Patients were sent reminders by text or email to complete Symptom Screening in Pediatrics Tool (SSPedi) three times weekly for eight weeks. When patients reported at least one severely bothersome symptom, the symptom report was emailed to the primary healthcare team. Patient-reported outcomes were obtained at baseline, week 4 ± 1 and week 8 ± 1. Symptom documentation, intervention provision for symptoms and unplanned healthcare encounters were determined by chart review at weeks 4 and 8. The primary endpoint was feasibility, defined as at least 75% patients achieving adherence with at least 60% of SSPedi evaluations. We planned to enroll successive cohorts until this threshold was met. Two cohorts consisting of 30 patients (cohort 1 (n = 20) and cohort 2 (n = 10)) were required to meet the feasibility threshold. In cohort 1, 11/20 (55%) met the SSPedi completion threshold. Interventions applied after cohort 1 included engaging parents to facilitate pediatric patient self-report, offering mechanisms to remember username and password and highlighting potential benefits of symptom feedback to clinicians. In cohort 2, 9/10 (90%) met the SSPedi completion threshold and thus feasibility was met. Patient-reported outcomes and chart review outcomes were obtained for all participants in cohort 2. Three times weekly symptom reporting by pediatric patients with cancer for eight weeks was feasible. Mechanisms to enhance three times weekly symptom reporting were identified and implemented. Future studies of longitudinal symptom screening can now be planned.